Cure8 news brief
A new bispecific antibody program (TL1A x IL-23p19) advancing toward patient trials could expand treatment options for people with ulcerative colitis and Crohn’s disease if later-stage trials confirm safety and efficacy. The financing/merger aims to provide capital to reach Phase 2.
Patients with ulcerative colitis or Crohn’s disease interested in experimental biologic therapies, clinicians who follow emerging IBD treatments, researchers in IBD immunology and drug development, and patients on biologics monitoring pipeline advances.
Caldera’s investigational drug CLD-423 is a bispecific antibody designed to block TL1A and IL-23p19 simultaneously.
The company reports Phase 1 single-ascending-dose data in healthy volunteers (completed dosing) showing favorable tolerability, long half-life, subcutaneous bioavailability, low anti-drug antibody incidence in early cohorts, and target engagement measures that support moving into patient efficacy trials.
The merger is structured as an all-stock transaction; the combined company plans to operate as Caldera Therapeutics and pursue a Nasdaq listing, with a concurrent private placement (~$278M) intended to fund operations into 2029 and support Phase 2 trials in ulcerative colitis and Crohn’s disease.
Caldera holds rights to CLD-423 under a license and expects to report additional Phase 1 data (including multiple-dose cohorts) later in 2026.
Early Phase 1 data reported here come from healthy volunteer cohorts and are preliminary; they describe tolerability, pharmacokinetics, and target engagement rather than efficacy in patients. The announcement is a company press release tied to a financing and merger, so it mixes clinical updates with corporate and funding information.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This is early-stage research about combining antibody targets (α4β7 and TL1A) for IBD; if validated in humans, combination biologics could offer improved effectiveness or dosing convenience.
Clinical trials expand treatment options and are how new IBD therapies are tested and approved. Low enrollment can delay access to future treatments for Crohn’s and ulcerative colitis.
The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...
